SND1 acts downstream of TGFβ1 and upstream of Smurf1 to promote breast cancer metastasis

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1275-1286

  Yu, Lin ^a   Liu, Xin ^a   Cui, Kang ^a   Di, Yanbo ^a   Xin, Lingbiao ^a   Sun, Xiaoming ^a   Zhang, Wei ^a   Yang, Xi ^b   Wei, Minxin ^a   Yao, Zhi ^a   Yang, Jie ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; PROTEIN P100; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMURF1 PROTEIN; STAPHYLOCOCCAL NUCLEASE DOMAIN CONTAINING 1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; RHOA PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMURF1 PROTEIN, HUMAN; SND1 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER TISSUE; CELL ADHESION; CELL INVASION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SND1 GENE; TRANSCRIPTION REGULATION; UBIQUITINATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; METABOLISM; NUDE MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTEOLYSIS; RHOA GTP-BINDING PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84932640122     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2387     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Laohavinij S, Ruikchuchit K, Maneechavakajorn J. Survival and prognostic factors of stage I-III breast cancer. J Med Assoc Thai 2013;96 Suppl 3:S23-34.
3. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909-14.
4. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006;66:6327-35.
5. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-3.
6. Gupta J, Robbins J, Jilling T, Seth P. TGFbeta-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 2011;11:311-6.
7. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol Cell Biol 2005;25:4703-15.
8. Theohari I, Giannopoulou I, Magkou C, Nomikos A, Melissaris S, Nakopoulou L. Differential effect of the expression of TGF-beta pathway inhibitors, Smad-7 and Ski, on invasive breast carcinomas: relation to biologic behavior. APMIS 2012;120:92-100.
9. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002;296:1646-7.
10. He Y, Zhang H, Yung A, Villeda SA, Jaeger PA, Olayiwola O, et al. ALK5-dependent TGF-beta signaling is a major determinant of late-stage adult neurogenesis. Nat Neurosci 2014;17:943-52.
11. Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, et al. Novel breast cancer metastasis-associated proteins. J Proteome Res 2009;8:583-94.
12. Blanco MA, Aleckovic M, Hua Y, Li T, Wei Y, Xu Z, et al. Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-interacting protein with metastasis-promoting functions. J Biol Chem 2011;286:19982-92.
13. Liu X, Dong L, Zhang X, Wang B, Wang X, Li H, et al. Identification of p100 target promoters by chromatin immunoprecipitation-guided ligation and selection (ChIP-GLAS). Cell Mol Immunol 2011;8:88-91.
14. Zhao WJ, Wang K. NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. Int J Oncol 2013;42:2060-8.
15. Pan H, Ding E, Hu M, Lagoo AS, Datto MB, Lagoo-Deenadayalan SA. SMAD4 is required for development of maximal endotoxin tolerance. J Immunol 2010;184:5502-9.
16. Naito Y, Yamada T, Matsumiya T, Ui-Tei K, Saigo K, Morishita S. dsCheck: highly sensitive off-target search software for double-stranded RNA-mediated RNA interference. Nucleic Acids Res 2005;33:W589-91.
17. Chau JF, Jia D, Wang Z, Liu Z, Hu Y, Zhang X, et al. A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nat Commun 2012;3:836.
18. Siemens N, Patenge N, Otto J, Fiedler T, Kreikemeyer B. Streptococcus pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte invasion via integrin-integrin-linked kinase (ILK) pathways and protects from macrophage killing. J Biol Chem 2011;286:21612-22.
19. Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, Kalkkinen N, et al. Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J 2002;21:4950-8.
20. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011;13:215.
21. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11:1287-96.
22. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol 1999;19:2495-504.
23. Sahai E, Garcia-Medina R, Pouyssegur J, Vial E. Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. J Cell Biol 2007;176:35-42.
24. Wang HR, Zhang Y, Ozdamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 2003;302:1775-9.
25. Townsend TA, Wrana JL, Davis GE, Barnett JV. Transforming growth factor-beta-stimulated endocardial cell transformation is dependent on Par6c regulation of RhoA. J Biol Chem 2008;283:13834-41.
26. Aguilar-Rojas A, Huerta-Reyes M, Maya-Nunez G, Arechavaleta-Velasco F, Conn PM, Ulloa-Aguirre A, et al. Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231. BMC Cancer 2012;12:550.
27. Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology 2011;53:1538-48.
28. Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, Miki K, et al. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol 2009;174:2044-50.
29. Wang N, Du X, Zang L, Song N, Yang T, Dong R, et al. Prognostic impact of Metadherin-SND1 interaction in colon cancer. Mol Biol Rep 2012;39:10497-504.
30. Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Saarikettu J, et al. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene 2014;33:3794-802.
31. Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res 2012;350:119-26.
32. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem 2012;287:13952-8.
33. Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura T, Nakagama H. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res 2007;67:9568-76.
34. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003;201:562-72.
35. Nakata D, Hamada J, Ba Y, Matsushita K, Shibata T, Hosokawa M, et al. Enhancement of tumorigenic, metastatic and in vitro invasive capacity of rat mammary tumor cells by transforming growth factor-beta. Cancer Lett 2002;175:95-106.
36. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002;62:497-505.
37. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005;307:1603-9.
38. Wang HR, Ogunjimi AA, Zhang Y, Ozdamar B, Bose R, Wrana JL. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods Enzymol 2006;406:437-47.
39. Shi JW, Liu W, Zhang TT, Wang SC, Lin XL, Li J, et al. The enforced expression of c-Myc in pig fibroblasts triggers mesenchymal-epithelial transition (MET) via F-actin reorganization and RhoA/Rock pathway inactivation. Cell Cycle 2013;12:1119-27.